Sugi Predict

Sugi Predict / Compounds / SCHEMBL2799080

SCHEMBL2799080

SCHEMBL2799080

COc1cc(=O)[nH]c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 2/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ CYP2C19 P33261 1/20 0.61
▸ KMT2A Q03164 4/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ GFER P55789 1/20 0.56
▸ KDM4E B2RXH2 3/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ ABCG2 Q9UNQ0 3/20 0.54
▸ NQO2 P16083 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ HPGD P15428 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ AR P10275 1/20 0.52
▸ ATM Q13315 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ IGF1R P08069 1/20 0.51
▸ GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31664571 1.00 TNKS2 (0.61) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL13429106 0.89 KMT2A (0.53) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL13429062 0.84 L3MBTL1 (0.60) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL8987152 0.83 TNKS2 (0.59) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL9029582 0.81 CYP1A2 (0.56) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL13429074 0.81 ABCG2 (0.51) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL11380959 0.81 KDM4E (0.56) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL12533056 0.79 AR (0.57) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL2008835 0.79 HPGD (0.54) TNKS2CYP1A2CYP2C19KMT2AMEN1
SCHEMBL13429105 0.78 TNKS2 (0.62) TNKS2CYP1A2CYP2C19KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111850631-B High-gloss decorative rhodium-plated layer electroplating solution 金川集团股份有限公司 2021-10-08 — — CN claimed
CN-111850631-A High-gloss decorative rhodium-plated layer electroplating solution 金川集团股份有限公司 2020-10-30 — — CN claimed
CN-111850631-B High-gloss decorative rhodium-plated layer electroplating solution 金川集团股份有限公司 2021-10-08 — — CN disclosed
CN-111850631-A High-gloss decorative rhodium-plated layer electroplating solution 金川集团股份有限公司 2020-10-30 — — CN disclosed
EP-2727594-A1 NOVEL PHARMACEUTICAL COMPOSITION Mitsubishi Tanabe Pharma Corporation (JP) 2014-05-07 — — EP disclosed
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 — — US disclosed
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 — — US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-23 — — US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 — — US disclosed
EP-1343499-A4 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2004-05-06 — — EP disclosed
US-20040067997-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents YU KUO-LONG (US) 2004-04-08 — — US disclosed
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2003-11-06 — — US disclosed
EP-1343499-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-09-17 — — EP disclosed
WO-2003053344-A2 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 — — WO disclosed
WO-2002062290-A2 HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-15 — — WO disclosed
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2002-07-25 — — US disclosed
WO-2002026713-A1 ANTIPARASITIC COMPOUNDS KING'S COLLEGE LONDON (GB) 2002-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents MAVS, ZC3HAV1, EIF2AK2 TNKS2 1010/4885CYP1A2 1326/4885CYP2C19 678/4885
US-20040067997-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents MAVS, ZC3HAV1, EIF2AK2 TNKS2 1010/4885CYP1A2 1326/4885CYP2C19 678/4885
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents MAVS, ZC3HAV1, EIF2AK2 TNKS2 1520/4885CYP1A2 1430/4885CYP2C19 752/4885
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION NQO2, ASNS, NDUFS1 TNKS2 1696/4885CYP1A2 1206/4885CYP2C19 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.